Caja Costarricense de Seguro Social
Quick facts
Marketed products
- Risankizumab (RISA) · Immunology
Risankizumab is a monoclonal antibody that selectively inhibits the IL-23 cytokine pathway by binding to the p19 subunit of IL-23.
Phase 2 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Caja Costarricense de Seguro Social portfolio CI brief
- Caja Costarricense de Seguro Social pipeline updates RSS
Frequently asked questions about Caja Costarricense de Seguro Social
What are Caja Costarricense de Seguro Social's marketed drugs?
Top marketed products include Risankizumab (RISA).
Related
- Risankizumab (RISA) · Immunology
- Sector hub: All tracked pharma companies